𝔖 Bobbio Scriptorium
✦   LIBER   ✦

[AAPS Advances in the Pharmaceutical Sciences Series] Drug Delivery to the Brain Volume 10 || Intranasal Drug Delivery to the Brain

✍ Scribed by Hammarlund-Udenaes, Margareta; de Lange, Elizabeth C.M.; Thorne, Robert G.


Book ID
125473085
Publisher
Springer New York
Year
2013
Tongue
English
Weight
984 KB
Edition
2014
Category
Article
ISBN
1461491053

No coin nor oath required. For personal study only.

✦ Synopsis


The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood –brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g. active/passive transport across the BBB, intra-brain distribution, and central/systemic pharmacokinetics, to name a few.Β Neurological disease and trauma conditions add further complexity because CNS barriers, drug distribution and pharmacokinetics are dynamic and often changed by disease/trauma. Knowledge of all these factors and their interplay in different conditions is of utmost importance for proper CNS drug development and disease treatment. In recent years much information has become available for a better understanding ofΒ the many factors important for CNS drug delivery and how they interact to affect drug action. This book describes small and large drug delivery to the brain with an emphasis on the physiology of the BBB and the principles and concepts for drug delivery across the BBB and distribution within the brain. It contains methods descriptions for studying drug delivery, routes and approaches of administering drugs into the brain, the influence of disease, and drug industry perspectives. Therewith, it contributes to an in-depth understanding of the interplay between brain (patho)-physiology and drug characteristics. Furthermore, the content is designed to be both cutting-edge and educational, so that the book can be used in high-level training of academic and industry scientists with full references to original publications. Β  Β  ​


πŸ“œ SIMILAR VOLUMES


[AAPS Advances in the Pharmaceutical Sci
✍ Hammarlund-Udenaes, Margareta; de Lange, Elizabeth C.M.; Thorne, Robert G. πŸ“‚ Article πŸ“… 2013 πŸ› Springer New York 🌐 English βš– 272 KB

The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood –brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g. active/p

[AAPS Advances in the Pharmaceutical Sci
✍ Hammarlund-Udenaes, Margareta; de Lange, Elizabeth C.M.; Thorne, Robert G. πŸ“‚ Article πŸ“… 2013 πŸ› Springer New York 🌐 English βš– 274 KB

The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood –brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g. active/p

[AAPS Advances in the Pharmaceutical Sci
✍ Bar-Shalom, Daniel; Rose, Klaus πŸ“‚ Article πŸ“… 2014 πŸ› Springer New York 🌐 English βš– 330 KB

Until the 1990s, it was generally accepted that medicines were first developed for adults and their use in children was investigated later, if at all. One of the main tasks of hospital pharmacies was the manufacturing of child-appropriate formulations in a more or less makeshift way. The first chang

[AAPS Advances in the Pharmaceutical Sci
✍ Bar-Shalom, Daniel; Rose, Klaus πŸ“‚ Article πŸ“… 2014 πŸ› Springer New York 🌐 English βš– 436 KB

Until the 1990s, it was generally accepted that medicines were first developed for adults and their use in children was investigated later, if at all. One of the main tasks of hospital pharmacies was the manufacturing of child-appropriate formulations in a more or less makeshift way. The first chang